Connect with us

Health

University of Toronto Study Finds Teen Marijuana Use Tied To Dramatic Increased Risk Of Psychosis

Published

3 minute read

From the Daily Caller News Foundation

By KATE ANDERSON

 

A study published Wednesday found that teens who use cannabis are 11 times more likely to be diagnosed with a psychotic disorder, according to NBC News.

The study was led by researchers from the University of Toronto and examined teenage patients who used cannabis within the last year and those who did not, according to NBC News. When the study was further limited to teens who were sent to the emergency room or hospitalized, it showed a 27-fold increase in the likelihood of being diagnosed with psychotic illness.

“I think that there’s enough evidence out there for us to give recommendations that teens probably shouldn’t be using cannabis,” Andre McDonald, a postdoctoral research fellow at McMaster University and lead author of the study, said, according to NBC News. “If we can somehow ask teens to delay their use until their brain has developed a little further, I think that would be good for public health.”

While the research does not prove that cannabis use by teens causes psychosis, Dr. Leslie Hulvershorn, a child psychiatrist who was not involved with the study, argued it was unlikely that the teens were already predisposed to these kinds of mental health issues, according to NBC News. The study noted that the risk of psychosis did not spike for users between the ages of 20 and 33 and Dr. Kevin Gray, a professor of psychiatry at the Medical University of South Carolina who was not a part of the study, told NBC News that the increase in risk of psychosis likely had to do with brain development at different stages of life.

“There’s something about that stage of brain development that we haven’t yet fully characterized — where there’s a window of time where cannabis use may increase the risk of psychosis,” Gray said. “This study really puts a fine point on delaying cannabis use until your 20s may mitigate one of the most potentially serious risks.”

Another study from July 2023 found that marijuana addiction made individuals four times more likely to later be diagnosed with bipolar disorder with psychotic symptoms and two times more likely to be diagnosed with depression. Recreational marijuana use has been legalized in 24 states and Washington D.C., and 13 states have legalized the substance for medical use, according to CBS News.

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

Business

Trump signs order reclassifying marijuana as Schedule III drug

Published on

From The Center Square

By

President Donald Trump signed an executive order moving marijuana from a Schedule I to a Schedule III controlled substance, despite many Republican lawmakers urging him not to.

“I want to emphasize that the order I am about to sign is not the legalization [of] marijuana in any way, shape, or form – and in no way sanctions its use as a recreational drug,” Trump said. “It’s never safe to use powerful controlled substances in recreational manners, especially in this case.”

“Young Americans are especially at risk, so unless a drug is recommended by a doctor for medical reasons, just don’t do it,” he added. “At the same time, the facts compel the federal government to recognize that marijuana can be legitimate in terms of medical applications when carefully administered.”

Under the Controlled Substances Act, Schedule I drugs are defined as having a high potential for abuse and no accepted medical use. Schedule III drugs – such as anabolic steroids, ketamine, and testosterone – are defined as having a moderate potential for abuse and accepted medical uses.

Although marijuana is still illegal at the federal level, 24 states and the District of Columbia have fully legalized marijuana within their borders, while 13 other states allow for medical marijuana.

Advocates for easing marijuana restrictions argue it will accelerate scientific research on the drug and allow the commercial marijuana industry to boom. Now that marijuana is no longer a Schedule I drug, businesses will claim an estimated $2.3 billion in tax breaks.

Chair of The Marijuana Policy Project Betty Aldworth said the reclassification “marks a symbolic victory and a recalibration of decades of federal misclassification.”

“Cannabis regulation is not a fringe experiment – it is a $38 billion economic engine operating under state-legal frameworks in nearly half of the country that has delivered overall positive social, educational, medical, and economic benefits, including correlation with reductions in youth use in states where it’s legal,” Aldworth said.

Opponents of the reclassification, including 22 Republican senators who sent Trump a warning letter Wednesday, point out the negative health impact of marijuana use and its effects on occupational and road safety.

“The only winners from rescheduling will be bad actors such as Communist China, while Americans will be left paying the bill. Marijuana continues to fit the definition of a Schedule I drug due to its high potential for abuse and its lack of an FDA-approved use,” the lawmakers wrote. “We cannot reindustrialize America if we encourage marijuana use.”

Marijuana usage is linked to mental disorders like depression, suicidal ideation, and psychotic episodes; impairs driving and athletic performance; and can cause permanent IQ loss when used at a young age, according to the Substance Abuse and Mental Health Administration.

Additionally, research shows that “people who use marijuana are more likely to have relationship problems, worse educational outcomes, lower career achievement, and reduced life satisfaction,” SAMHA says.

Continue Reading

Health

Saskatchewan woman approved for euthanasia urged to seek medical help in Canada rather than US

Published on

From LifeSiteNews

By Anthony Murdoch

Saskatchewan Premier Scott Moe encouraged Jolene Van Alstine, who has a rare disease, to work with his government on a solution.

Saskatchewan Premier Scott Moe is urging a woman with a rare disease, who has been approved to die by euthanasia because she can’t get proper care, to instead work with his government on a solution.

As reported by LifeSiteNews last week, Saskatchewan resident Jolene Van Alstine was approved to die by state-sanctioned euthanasia because she has had to endure long wait times for what she considers to be proper care for a rare parathyroid disease.

Van Alstine’s condition, normocalcemic primary hyperparathyroidism (nPHPT), causes her to experience vomiting, nausea, and bone pain.

As a result of Van Alstine’s frustrations with the healthcare system, she applied for Canada’s Medical Assistance in Dying (MAiD) and was approved for a January 7, 2026, death date.

Her case drew the attention of American media personality Glenn Beck, who has been in contact with Van Alstine to determine whether she can get the surgery done in the United States. Even the administration of U.S. President Donald Trump has been briefed on the matter.

According to Moe, Van Alstine has taken her case to Saskatchewan Health Minister Jeremy Cockrill, asking for help.

“There has been an opportunity to see specialists in Saskatchewan and outside of Saskatchewan, and those conversations about maybe potentially seeing additional specialists continue with the minister’s office and the Ministry of Health,” Moe said yesterday at a press conference.

“I would hope that she’d continue to work with the Ministry of Health, because I think there’s work going on to see even additional specialists at this point,”

A recent Euthanasia Prevention Coalition report revealed that Canada has euthanized 90,000 people since 2016, the year it was legalized.

As reported by LifeSiteNews, over 23,000 Canadians have died while on wait lists for medical care as Prime Minister Mark Carney’s Liberal government focuses on euthanasia expansions.

Continue Reading

Trending

X